Publications by authors named "Ajit Chavan"
Article Synopsis
- * Two studies tested how well vadadustat works when taken with phosphate binders and iron supplements, finding that its effectiveness decreased when these were taken together.
- * Taking vadadustat one hour before phosphate binders minimized negative interactions and the drug was generally well tolerated by participants in both studies.
Article Synopsis
- * The study found that while plasma exposure to vadadustat was higher in those with moderate liver impairment, the maximum concentration of the drug was similar in both groups, indicating that liver function may not significantly impact how the drug is processed in the body.
- * Overall, the drug was well tolerated with mostly mild side effects, suggesting that it could be safe for use in individuals with some degree of liver impairment.
The emergence and spread of multidrug-resistant (MDR) Gram negative bacteria presents a serious threat for public health. Novel antimicrobials that could overcome the resistance problems are urgently needed. UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) is a cytosolic zinc-based deacetylase that catalyzes the first committed step in the biosynthesis of lipid A, which is essential for the survival of Gram-negative bacteria.
View Article and Find Full Text PDFPurpose: VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity of VS-6063 in Japanese subjects with advanced solid tumor malignancies in a first-in-Asian study setting.
Methods: VS-6063 was administered orally twice daily (b.
The emergence and spread of multidrug resistant bacteria are widely believed to endanger human health. New drug targets and lead compounds exempt from cross-resistance with existing drugs are urgently needed. We report on the discovery of azaindole ureas as a novel class of bacterial gyrase B inhibitors and detail the story of their evolution from a de novo design hit based on structure-based drug design.
View Article and Find Full Text PDFIvacaftor is approved in the USA for the treatment of cystic fibrosis (CF) in patients with a G551D-CFTR mutation or one of eight other CFTR mutations. A series of in vitro experiments conducted early in the development of ivacaftor indicated ivacaftor and metabolites may have the potential to inhibit cytochrome P450 (CYP) 2C8, CYP2C9, CYP3A, and CYP2D6, as well as P-glycoprotein (P-gp). Based on these results, a series of clinical drug-drug interaction (DDI) studies were conducted to evaluate the effect of ivacaftor on sensitive substrates of CYP2C8 (rosiglitazone), CYP3A (midazolam), CYP2D6 (desipramine), and P-gp (digoxin).
View Article and Find Full Text PDF